Literature DB >> 11053620

Expression and characterization of recombinant protein S with the Ser 460 Pro mutation.

O Morboeuf1, D Borgel, M Aiach, T Kaabache, S Gandrille, P Gaussem.   

Abstract

To characterize the putative biochemical modifications induced by the Ser 460 to Pro (Heerlen) mutation in protein S (PS), we expressed both wild-type (wt) and mutated recombinant PS in HEK cells. In SDS-polyacrylamide gels, r-PS Heerlen migrated at 71 kDa whereas r-wt PS migrated at 73 kDa, a difference abolished after deglycosylation by N-glycosidase, suggesting that the Ser 460 Pro mutation abolishes N-glycosylation of Asn 458. The affinity of r-wt PS and r-PS Heerlen for C4b-binding protein (C4b-BP) and for phospholipid vesicles was similar. Neither the enhancement of APC-dependent prolongation of the APTT, nor the specific enhancement of FVa and FVIIIa proteolysis by APC in purified systems was affected by the mutation. However, the Ser 460 Pro mutation induced a slight conformational change in the SHBG domain of the PS molecule, as shown by reduced binding affinity for monoclonal antibodies. The type III phenotype associated with the Heerlen mutation might thus result from a slightly modified rate of synthesis or catabolism. The resulting moderate decrease in the circulating PS concentration may modify the equilibrium between free PS and C4b-BP/PS complexes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053620     DOI: 10.1016/s0049-3848(00)00296-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain.

Authors:  D Borgel; P Gaussem; C Garbay; C Bachelot-Loza; T Kaabache; W Q Liu; B Brohard-Bohn; B Le Bonniec; M Aiach; S Gandrille
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

2.  Alternative mRNA is favored by the A3 haplotype of the EPCR gene PROCR and generates a novel soluble form of EPCR in plasma.

Authors:  Beatrice Saposnik; Elodie Lesteven; Anna Lokajczyk; Charles T Esmon; Martine Aiach; Sophie Gandrille
Journal:  Blood       Date:  2007-12-11       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.